Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CorMedix (CRMD) Gross Profit (2016 - 2025)

CorMedix's Gross Profit history spans 12 years, with the latest figure at $107.3 million for Q4 2025.

  • For Q4 2025, Gross Profit rose 257.28% year-over-year to $107.3 million; the TTM value through Dec 2025 reached $275.7 million, up 584.54%, while the annual FY2025 figure was $275.7 million, 584.54% up from the prior year.
  • Gross Profit for Q4 2025 was $107.3 million at CorMedix, up from $93.1 million in the prior quarter.
  • Across five years, Gross Profit topped out at $107.3 million in Q4 2025 and bottomed at -$818539.0 in Q1 2024.
  • The 4-year median for Gross Profit is $28109.0 (2021), against an average of $19.8 million.
  • The largest annual shift saw Gross Profit crashed 127.51% in 2021 before it skyrocketed 12683.29% in 2025.
  • A 4-year view of Gross Profit shows it stood at $8390.0 in 2021, then soared by 249.18% to $29296.0 in 2022, then skyrocketed by 102421.64% to $30.0 million in 2024, then surged by 257.28% to $107.3 million in 2025.
  • Per Business Quant, the three most recent readings for CRMD's Gross Profit are $107.3 million (Q4 2025), $93.1 million (Q3 2025), and $37.9 million (Q2 2025).